一、关于公司 2025 年第一季度报告的独立意见 广州洁特生物过滤股份有限公司 独立董事关于公司第四届董事会第十九次会议 相关事项的独立意见 根据中国证监会《上市公司独立董事管理办法》《上海证券交易所科创板股 票上市规则》及《公司章程》等有关规定，我们作为广州洁特生物过滤股份有限 公司（以下简称"公司"）独立董事，本着对公司、全体股东负责的态度，基于 独立、客观、审慎的原则，现就公司第四届董事会第十九次会议审议的相关事项 发表如下独立意见： 广州洁特生物过滤股份有限公司独立董事 洪炜、刘佳、陈锦棋 2025 年 4 月 25 日 1 我们认为，公司严格按照《证券法》《上海证券交易所科创板股票上市规则》 等有关规定，编制了 2025 年第一季度报告，真实、准确、完整地反映了公司 2025 年第一季度的财务状况和经营成果。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于近日收到保荐机构 民生证券股份有限公司（以下简称"民生证券"）《关于变更持续督导保荐代表人 的函》。 民生证券作为公司 2022 年向不特定对象发行可转换公司债券项目的保荐机 构，指定陈思捷先生和卢景芳女士为持续督导保荐代表人，法定持续督导期限至 2024 年 12 月 31 日。因上述期限届满后公司募集资金尚未使用完毕，民生证券 仍需就公司尚未使用完毕的募集资金履行持续督导义务。 由于陈思捷先生和卢景芳女士工作发生变动，无法继续从事对公司的持续督 导工作。为保证持续督导工作的有序进行，民生证券现委派李东茂先生和张春晖 先生（简历附后）接替陈思捷先生和卢景芳女士的工作，继续履行对公司的持续 督导保荐责任。 本次保荐代表人变更后，公司持续督导的保荐代表人为李东茂先生和张春晖 先生，继续履行相关的职责和义务，直至相关工作全部结束。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-027 | | --- ...

1、以 3 票同意，0 票反对，0 票弃权，审议通过了《关于 2025 年第一季度报 告的议案》。 经审核，公司 2025 年第一季度报告的编制和审议程序符合相关法律法规及《公 司章程》等内部规章制度的规定；公司 2025 年第一季度报告的内容与格式符合相 关规定，公允地反映了公司 2025 年第一季度的财务状况和经营成果等事项；报告 编制过程中，未发现公司参与报告编制和审议的人员有违反保密规定的行为；监事 会全体成员保证公司 2025 年第一季度报告披露的信息真实、准确、完整，不存在 任何虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 公司《2025 年第一季度报告》于本公告同日刊登在上海证券交易所网站。 特此公告。 | 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-026 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 第四届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥123,822,565.32, representing a 26.00% increase compared to ¥98,275,342.97 in the same period last year[3] - Net profit attributable to shareholders increased by 101.29% to ¥16,462,336.91 from ¥8,178,548.18 year-on-year[3] - The net profit after deducting non-recurring gains and losses surged by 269.23% to ¥15,649,184.18, up from ¥4,238,346.03 in the previous year[3] - Basic and diluted earnings per share increased by 71.43% to ¥0.12 from ¥0.07 year-on-year[3] - Operating profit for Q1 2025 was ¥20,776,144.08, up 104.5% from ¥10,154,055.81 in Q1 2024[20] - The company reported a total comprehensive income of ¥17,269,421.38 for Q1 2025, significantly higher than ¥8,157,187.58 in Q1 2024[20] Cash Flow and Assets - The net cash flow from operating activities improved by 29.44%, totaling ¥45,697,941.98 compared to ¥35,304,971.53 in the same quarter last year[3] - Cash flow from operating activities for Q1 2025 was ¥45,697,941.98, an increase from ¥35,304,971.53 in Q1 2024[21] - Cash and cash equivalents at the end of Q1 2025 totaled ¥157,629,740.36, compared to ¥351,723,580.60 at the end of Q1 2024[22] - The company's current assets totaled CNY 779,673,740.26, a decrease from CNY 797,452,518.69 in the previous period[16] - The company's cash and cash equivalents increased to CNY 302,498,940.36 from CNY 284,205,896.01[15] - Total assets at the end of the reporting period were ¥1,704,544,451.20, a slight increase of 0.15% from ¥1,702,023,099.33 at the end of the previous year[4] Research and Development - The company's R&D investment totaled ¥5,846,178.82, a decrease of 10.02% compared to ¥6,497,446.91 in the same period last year[3] - R&D expenditure as a percentage of revenue decreased by 1.89 percentage points to 4.72% from 6.61% year-on-year[4] - Research and development expenses for Q1 2025 were ¥5,846,178.82, a decrease of 10% from ¥6,497,446.91 in Q1 2024[19] Legal Matters - The company is involved in a legal dispute with Shandong Darong New Materials Co., with a claimed amount of RMB 10,866,391.80 for goods and additional costs[12] - The court ruled in favor of the company in the second instance, ordering Shandong Darong to return RMB 7,962,686.40 and interest[12] - The company is actively pursuing legal actions to recover funds and protect its interests in ongoing disputes[12] - The company is preparing for potential future litigation related to the ongoing disputes with Shandong Darong and other parties[12] - The company is involved in a legal dispute with Shenzhen Hosheng Medical Technology Co., Ltd. regarding a mold procurement contract, with a claimed amount of CNY 10,340,829 and a compensation claim of CNY 644,911[13] - The court ruled in March 2023 to terminate the contract and ordered Hosheng Medical to refund the payment, but Hosheng Medical appealed the decision, leading to a retrial[13] - A subsidiary, Baifeier, is in litigation with Shanghai Deyou Electronic Technology Co., Ltd. over a PTFE nano film sales contract, with a claimed amount of CNY 18,441,691.80 and a penalty of CNY 1,386,000[13] - The court ruled in August 2024 to terminate the contract and ordered the return of the payment and a penalty, but the defendant has appealed the decision[13] Shareholder Information - The top shareholder, Yuan Jianhua, holds 41,032,960 shares, representing a significant portion of the company's equity[11] - JET (H.K.) BIOSCIENCE CO., LIMITED, a related party, holds 17,547,293 shares, indicating a close connection to the company's management[11] - The company has a diverse shareholder base, with the top ten shareholders holding a total of 67,000,000 shares[11] Liabilities and Equity - The total liabilities decreased to CNY 490,235,036.66 from CNY 504,983,106.17[17] - The company's equity attributable to shareholders increased to CNY 1,206,186,380.40 from CNY 1,189,780,067.07[18]

Group 1 - The core viewpoint of the article highlights that Jiet Bio reported a revenue of 124 million yuan for the first quarter of 2025, representing a year-on-year growth of 26.00% [1] - The net profit for the same period was 16.46 million yuan, showing a significant year-on-year increase of 101.29% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688026 证券简称：洁特生物 公告编号：2025-025 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于召开2024年度暨2025年第一季度 业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2025年4月28日（星期一）下午14:00-15:00 ●会议召开地点： 上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ●投资者可于2025年4月21日（星期一）至4月25日（星期五）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱jetzqb@jetbiofil.com进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 广州洁特生物过滤股份有限公司（以下简称"公司"）已于2025年4月16日发布公司2024年年度报告，并 将于2025年4月26日发布公司20 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于 2025 年 4 月 21 日（星期一）至 4 月 25 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jetzqb@jetbiofil.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-025 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 暨现金分红说明会的公告 3、会议召开方式：上证路演中心网络互动 三、参会人员 广州洁特生物过滤股份有限公司（以下简称"公司"）已于 2025 年 4 月 16 日发布公司 2024 年年度报告，并将 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and profitability recovery. Core Insights - The company achieved a revenue of 559 million yuan in 2024, representing a year-over-year increase of 20.63%, with a net profit of 72 million yuan, up 107.51% year-over-year [1][2] - The growth in revenue is attributed to the successful promotion of its overseas self-owned brands and the stable demand for life science products, particularly in cell culture and liquid handling segments [2] - The gross margin improved to 41.41% in 2024, an increase of 10.79 percentage points year-over-year, indicating a recovery in profitability [2] - Future revenue projections for 2025-2027 are 682 million, 827 million, and 992 million yuan, with corresponding net profits of 99 million, 122 million, and 150 million yuan, reflecting growth rates of 22.2%, 21.1%, and 20.0% respectively [2][3] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 559 million yuan, a 20.63% increase from 2023, with a net profit of 72 million yuan, marking a 107.51% increase [3] - The gross margin for 2024 was 41.41%, up from 30.6% in 2023, indicating improved cost management and pricing stability [3] - The company’s sales expenses were 6.15% of revenue, while management expenses were 8.13%, and R&D expenses were 4.70% [2] Revenue Breakdown - The revenue from biological culture products was 172 million yuan, up 9.08% year-over-year, while liquid handling products generated 337 million yuan, a 22.64% increase [2] - International revenue reached 351 million yuan, a 23.50% increase, with overseas self-owned brand income rising by 46.07% [2] Future Projections - Revenue forecasts for 2025, 2026, and 2027 are 682 million, 827 million, and 992 million yuan, with net profits projected at 99 million, 122 million, and 150 million yuan respectively [3] - The expected P/E ratios for 2025, 2026, and 2027 are 20, 16, and 13 times, indicating a favorable valuation trend [2][3]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and profitability recovery. Core Insights - The company achieved a revenue of 559 million yuan in 2024, representing a year-over-year increase of 20.63%, with a net profit of 72 million yuan, up 107.51% year-over-year [1][2] - The growth in revenue is attributed to the successful promotion of its overseas self-owned brands and the overall growth in its life sciences product business [2] - The gross profit margin improved to 41.41% in 2024, an increase of 10.79 percentage points year-over-year, indicating a recovery in profitability [2] - The company is expected to continue its growth trajectory with projected revenues of 682 million yuan, 827 million yuan, and 992 million yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 99 million yuan, 122 million yuan, and 150 million yuan [2][3] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 559 million yuan, a 20.63% increase from 2023, and a net profit of 72 million yuan, reflecting a 107.51% increase year-over-year [3] - The gross margin for 2024 was 41.41%, up from 30.6% in 2023, indicating improved cost management and pricing stability [3] Revenue Breakdown - The revenue from biological culture products reached 172 million yuan, growing by 9.08% year-over-year, while liquid handling products generated 337 million yuan, up 22.64% [2] - International sales accounted for 351 million yuan, a 23.50% increase, with overseas self-owned brand revenue rising by 46.07% [2] Future Projections - The company forecasts revenue growth of 22.2% in 2025, 21.1% in 2026, and 20.0% in 2027, with net profit growth rates of 37.4%, 22.7%, and 23.3% respectively [2][3]

本报讯(记者丁蓉)4月15日晚间，广州洁特生物过滤股份有限公司(以下简称"洁特生物")发布2024年度报 告。公告显示，公司2024年实现营业收入5.59亿元，同比增长20.63%；实现归属于上市公司股东的净利 润7218.96万元，同比增长107.51%。报告期内，公司毛利率41.41%，同比上年增加10.79个百分点，净 利率12.92%，同比上年增加5.41个百分点。 洁特生物2024年加强了海外的自主品牌产品销售。2024年度，公司海外自主品牌收入同比增加约 46.07%，自主品牌在境外的收入占比从2023年度的约15.98%提高到2024年度的约18.89%，提升约2.92个 百分点。洁特生物境内收入1.8亿元，占比约33.87%。细胞工厂产品是工艺要求相对较高的产品，公司 细胞工厂产品2024年销售额同比增长约28.55%，表现出良好的发展势头。 洁特生物2024年重点开发了储液袋、细胞培养袋、冻存袋、囊式过滤器、密闭系统、双侧壁细胞培养 瓶、透气静态细胞培养瓶等高端产品，并成功将自主研发的PES超滤膜应用于超滤离心管等系列产品， 显著提升了过滤效率与蛋白截留性能。同时，公司扩充了试剂类产品如胎牛 ...